Eye-care company Bausch & Lomb Inc. is nearing a deal to sell itself to Canadian drugmaker Valeant Pharmaceuticals International Inc. (VRX, VRX.TO) for about $9 billion, the Wall Street Journal reported Friday, citing people familiar with the matter.
According to the Journal, a deal could be struck next week, the people said, cautioning that the deal is not done yet and could still fall apart.
Bausch & Lomb is currently owned by private-equity firm Warburg Pincus LLC, which acquired the eye-care products maker in a leverage buyout in 2007 for about $4.5 billion, including about $830 million of debt.
Bausch & Lomb, based in Rochester, New York, is one of the world's largest suppliers of eye-care products, including contact lenses, lens care products, medicines and implants for eye diseases.
In March, Bausch & Lomb filed for an initial public offering of its common stock with the U.S. Securities and Exchange Commission, while Warburg Pincus continued to explore a private sale of the company.
Valeant, on the other hand, unsuccessfully tried earlier this year to buy integrated specialty pharmaceutical company Actavis, Inc. (ACT), which struck a deal earlier this week to buy Warner Chilcott Plc. (WCRX) for $8.5 billion in stock.
Valeant shares are currently trading at $83.72, up $9.05 or 12.12%. On the TSX, the company's shares are currently trading at C$86.08, up C$9.24 or 12.02%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.